CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 6, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Stephen Berenson to its Board of Directors. Mr. Berenson is a Managing Partner at Flagship Pioneering and previously spent his career as an investment banker at J.P. Morgan.
“Flagship Pioneering continues to view the microbiome as a rapidly emerging and highly promising field with vast therapeutic potential. We were pleased to extend our Seres ownership through a new investment fund, as part of the Company’s recent public equity offering. Stephen’s financial and strategic acumen will be valuable assets to the Seres Board,” said Noubar Afeyan, co-founder and Lead Director of Seres and Chief Executive Officer of Flagship Pioneering.
Eric Shaff, President and Chief Executive Officer of Seres commented, “Having founded Seres within its Flagship Labs unit, Flagship Pioneering has provided valuable long-term support to Seres and we deeply appreciate their continued engagement. Stephen Berenson is a highly accomplished corporate executive, and I am delighted to welcome him to the Board.”
“Seres is a clear leader in the development of microbiome therapeutics, and I am very pleased to join the Company’s Board. I am especially excited to join Seres ahead of the important clinical readouts anticipated in 2020, and the potential to create substantial long-term shareholder value while developing important new medicines,” said Mr. Berenson.
Prior to Flagship, Mr. Berenson spent 33 years in various roles as an investment banker at J.P. Morgan. During his last 12 years at J.P. Morgan, Mr. Berenson was Vice Chairman of Investment Banking, where he focused on providing high-touch strategic advice and complex transaction execution to leading companies across all industries globally. He was co-founder of J.P. Morgan’s Global Strategic Advisory Council and co-founder of the firm’s Board Initiative. Mr. Berenson also serves on the Board of Directors of Moderna, Inc. and CiBO Technologies, Inc. Mr. Berenson received an S.B. in mathematics from Massachusetts Institute of Technology.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres’ SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres is also developing SER-401 in a Phase 1b study in patients with metastatic melanoma. For more information, please visit www.serestherapeutics.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including Mr. Berenson’s potential contribution to the Company and the timing and results of the Company’s clinical studies.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on May 2, 2019 and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Carlo Tanzi, Ph.D., Seres Therapeutics, 617-203-3467
Vice President, Investor Relations and Corporate Communications